The development of KRAS-G12C inhibitors such as sotorasib and adagrasib has not led to curative outcomes in most patients with KRAS-mutant NSCLC, and those who respond to the treatment often exhibit resistance. Here, KRAS is linked to non-small cell lung carcinoma.